SECURITIES AND EXCHANGE COMMISSION

                            Washington, D.C.  20549


                                ______________


                                   FORM 8-K

                                CURRENT REPORT

                        Pursuant to Section 13 or 15(d)
                    of the Securities Exchange Act of 1934

                                ______________



Date of Report (Date of earliest event reported): November 6, 2000



                              CuraGen Corporation
            (Exact name of registrant as specified in its charter)


        Delaware                     0-23223                     06-1331400
   ------------------            --------------               ---------------
    (State or other               (Commission                  (IRS Employer
    jurisdiction of               File Number)               Identification No.)
     incorporation)

                       555 Long Wharf Drive, 11th Floor
                         New Haven, Connecticut 06511
                     ------------------------------------
              (Address of principal executive offices) (Zip Code)


Registrant's telephone number, including area code: (203) 401-3330

                     ------------------------------------


ITEM 5.   OTHER EVENTS.

     In a prospectus supplement dated November 6, 2000 that relates to the
Company's public offering of 4 million shares of its common stock, the Company
has disclosed the following:

     "Our scientists are using our Internet-based technology platform to
discover and assemble information on genes and proteins for use in discovering
and developing, and ultimately commercializing a proprietary line of protein and
antibody therapeutic products.  We have established internal development
programs to discover and develop therapeutic products to treat obesity and
diabetes, cancer, autoimmune and inflammatory diseases, and CNS disorders.

     To date, our discovery and development scientists have discovered and
characterized nearly 300 novel drug targets, including 50 potential protein
therapeutics, 96 antibody drug targets and 148 small molecule drug targets.
Over 60% of our potential protein therapeutics have been tested in animals.
Also, in conjunction with our collaborator, Abgenix, we have selected 30
antibody drug targets against which we intend to develop antibodies as potential
therapeutics for cancer, inflammation and autoimmune disease.  Over a five-year
period, Abgenix and we intend to develop antibodies against 120 drug targets,
test their efficacy as human therapeutics in cell and animal models, and develop
the most promising candidates as human therapeutics.

     We have made significant progress in our research and preclinical
development programs for novel protein and antibody therapeutics. We have
observed in cell and animal models promising results from a number of the
proteins that we have identified. We intend to develop a number of these
proteins as potential treatments for obesity, type II diabetes,
hypercholesterolemia and inflammatory bowel disease. We have also observed in
cell and human blood serum promising results from a novel, fully human antibody
that we discovered and may potentially develop as a treatment for various types
of cancer. The development of all of these potential therapeutics is at a very
early stage. Significant additional testing and development will be required
before we can determine if any of these candidates will progress to clinical
testing."

     This report on Form 8-K contains forward-looking statements about CuraGen
and some of its potential therapeutic products, including statements regarding
the development of antibodies and proteins as potential therapeutics.  While
management makes its best efforts to be accurate in making forward-looking
statements, any such statements are subject to risks and uncertainties that
could cause actual results to vary materially.  These risks include the
possibility of delays in the testing of potential therapeutic products, the risk
that preclinical trials may not result in successful clinical trials or
marketable products, the risk that CuraGen will be unable to successfully
finance, secure regulatory approval of and market any of its therapeutic product
candidates and CuraGen's reliance on research collaborations for the development
and testing of some of its potential therapeutic products.


ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS.

         (a) - (c)      Not Applicable.


                                 SIGNATURES

  Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                    CURAGEN CORPORATION
                                    (Registrant)



Date:  November 6, 2000             By: /s/  David Wurzer
                                        ------------------
                                        Executive Vice President and
                                        Chief Financial Officer